Beyond antipsychotic efficacy and toward an individualized therapeutic strategy: analysis of the systemic, metabolic, and inflammatory effects of olanzapine, haloperidol, and their combination in schizophrenic patients

Key Points

• Optimized clinical outcomes depend on understanding systemic effects.
• Individualized therapy may reduce long-term risks associated with antipsychotics.
• Evaluation of olanzapine and haloperidol shows differences in metabolic effects.
• Insights into inflammation may inform better treatment for schizophrenia.

Abstract